October 22, 2014

Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report

Case report


Open AccessAdile Berna Dursun and Osman Z Sahin
For all author emails, please log on.

Abstract (provisional)

Background

Allopurinol is an effective urate-lowering drug that is well tolerated by the majority of patients. Patients with chronic renal insufficiency have an increased risk of hypersensitivity reactions with allopurinol.

Case presentation

75 year old male patient with gout, renal insufficiency, history of metastatic colorectal carcinoma status post-resection was referred to Allergy clinic for a maculopapular eruption that developed 1 week after initiating therapy with allopurinol. The rash resolved with discontinuation of allopurinol. However, his serum urate level rose to 19.9 mg/dl. We initially proposed a slow 4 week oral allopurinol desensitization. The treating nephrologist felt it was critical to lower urate more rapidly. As a result, we modified the dose and standard 4 week protocol down to 2 weeks. A suspension of allopurinol was prepared by the allergy nurse practitioner with a 300 mg allopurinol tablet. The sensitization protocol was modified as a starting dose of 0.3 mg escalating to a final dose of 300 mg/day in 2 weeks. There was no reaction during or after the desensitization. The patient's urate level normalized (6.3 mg/dl) and has continued on 300 mg allopurinol daily without reaction.

Conclusion

A 2 week modified allopurinol desensitization protocol is a safe alternative for elderly patients with multiple comorbidities.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

No comments:

Post a Comment